利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

395 条记录 (耗时 0.03 秒)

    Sibutramine metabolites
    86.
    发明公开
    Sibutramine metabolites 审中-公开
    西布曲明代谢产物

    公开(公告)号：EP1475086A3

    公开(公告)日：2006-12-13

    申请号：EP04018454.1

    申请日：1999-08-23

    申请人： Sepracor Inc.

    发明人： Jerussi, Thomas, P. ,  Senanayake, Chrisantha, H. ,  Fang, Qun, K.

    IPC分类号： A61K31/13 ,  A61K31/135 ,  A61K31/137 ,  A61K31/11 ,  C07C251/18 ,  C07C47/457 ,  A61P3/04 ,  A61P15/10 ,  A61P25/00 ,  A61P25/06 ,  A61P25/08 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61P25/30 ,  A61P25/22 ,  A61P1/00

    CPC分类号： A61K45/06 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

    摘要： Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, incontinence, depresson, attention deficit disorder, attention deficit disorder with hyperactivity, bipolar and manic conditions, dysthymic disorder, and cyclothymic disorder, senile dementia, Alzheimer's type dementia, memory loss, amnesia/amnestic syndrome, disturbance of consciousness, coma, lowering of attention, speech disorders, Parkinson's disease, Lennox syndrome, autism, epilepsy, hyperkinetic syndrome and schizophrenia. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optionally pure sibutramine metabolites, wherein the sibutramine metabolite is selected from the group consisting of (+)-desmethylsibutramine, (-)-desmethylsibutramine, (±)-desmethylsibutramine, (+)-didesmethylsibutramine, (-)-didesmethylsibutramine, and (±)-didesmethylsibutramine.

    BENZO [D]ISOXAZOL-3-OL DAAO INHIBITORS
    88.
    发明公开
    BENZO [D]ISOXAZOL-3-OL DAAO INHIBITORS 审中-公开
    苯并[d]异恶唑-3- OL-DAAO-INHIBITOREN

    公开(公告)号：EP1711478A2

    公开(公告)日：2006-10-18

    申请号：EP04815603.8

    申请日：2004-12-28

    申请人： Sepracor Inc.

    发明人： FANG, Q. Kevin ,  HOPKINS, Seth ,  JONES, Steven

    IPC分类号： C07D263/00

    CPC分类号： C07D261/20

    摘要： Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia, or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutic amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof: I wherein Z1 is N or CR3; Z2 is N or CR4; Z3 is O or S; A is hydrogen, alkyl or M+; M is aluminum, calcium, lithium, magnesium, potassium, sodium, zinc or a mixture thereof; R1, R2, R3 and R4 are independently selected from hydrogen, alkyl, hydroxy alkoxy, aryl, acyl, halo, cyano, haloalkyl, NHCOOR5 and SO2NH2; R5 is aryl, arylalkyl, heteroaryl or heteroarylalkyl; at least one of R1, R2, R3 and R4 is other than hydrogen; and at least one of Z1 and Z2 is other than N.

    COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION
    89.
    发明公开
    COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION 有权
    镇静剂组合以及为改进抑郁症的治疗质量和睡眠的神经递质调制器和方法

    公开(公告)号：EP1691811A1

    公开(公告)日：2006-08-23

    申请号：EP04813295.5

    申请日：2004-12-08

    申请人： SEPRACOR, INC.

    发明人： LALJI, Karim ,  BARBERICH, Timothy, J. ,  CARON, Judy ,  WESSEL, Thomas

    IPC分类号： A61K31/4985 ,  A61K31/138 ,  A61P25/20 ,  A61P25/24

    CPC分类号： A61K31/4985 ,  A61K31/137 ,  A61K31/138 ,  A61K31/495 ,  A61K31/724 ,  A61K45/06 ,  A61K2300/00

    摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.

    DESMETHYLPANTOPRAZOLE COMPOSITIONS AND METHODS
    90.
    发明授权
    DESMETHYLPANTOPRAZOLE COMPOSITIONS AND METHODS 有权
    Desmethylpantoprazole的组合物和方法

    公开(公告)号：EP1075262B1

    公开(公告)日：2005-08-10

    申请号：EP99921682.3

    申请日：1999-05-05

    申请人： Sepracor Inc.

    发明人： YELLE, William, E.

    IPC分类号： A61K31/44 ,  A61K31/4439 ,  A61P1/04 ,  A61P17/06

    CPC分类号： A61K31/4439

    摘要： Methods and compositions are disclosed utilizing desmethylpantoprazole for the treatment of ulcers in humans. Desmethylpantoprazole exhibits a lessened liability toward drug-drug interactions than pantoprazole and a more predictable dosing regimen than pantoprazole. Desmethylpantoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.